Sequence LifeScience, Inc. Announces First Patient Enrolled in Groundbreaking Clinical Trial for Diabetic Foot Ulcers
Summary: Sequence LifeScience reported first-patient-in for a prospective, multicenter trial assessing outcomes of placental membrane allografts in hard-to-heal diabetic foot ulcers.
Key Highlights:
- Study aim: Evaluate wound closure and healing trajectory in chronic DFU using company’s allografts.
- Design: Prospective, multicenter clinical investigation focused on hard-to-heal ulcers.
- Rationale: Address persistent limb-loss risk and need for effective adjunctive biologics.
Read the press release on PR Newswire
Keywords:
Sequence LifeScience,
diabetic foot ulcer,
placental allograft,
clinical trial